Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Peter C Arden, Annie Baker, James C Bennett, Catherine Bird, Renske E Blom, Christine Brennan, Donna Brusch, Lisa Burke, Kete Campbell-Coker, Robin Carhart-Harris, Joseph Cattell, Aster Daniel, Charles DeBattista, Boadie W Dunlop, Katherine Eisen, David Feifel, MacKenzie Forbes, Hannah M Haumann, David J Hellerstein, Astrid I Hoppe, Muhammad I Husain, Luke A Jelen, Jeanine Kamphuis, Julie Kawasaki, John R Kelly, Richard E Key, Ronit Kishon, Stephanie Knatz Peck, Gemma Knight, Martijn H B Koolen, Melanie Lean, Rasmus W Licht, Jessica L Maples-Keller, Jan Mars, Lindsey Marwood, Martin C McElhiney, Tammy L Miller, Arvin Mirow, Sunil Mistry, Tanja Mletzko-Crowe, Liam N Modlin, René E Nielsen, Elizabeth M Nielson, Sjoerd R Offerhaus, Veronica O'Keane, Tomáš Páleníček, David Printz, Marleen C Rademaker, Aumer van Reemst, Frederick Reinholdt, Dimitris Repantis, James Rucker, Samuel Rudow, Simon Ruffell, A John Rush, Robert A Schoevers, Mathieu Seynaeve, Samantha Shao, Jair C Soares, Metten Somers, Susan C Stansfield, Diane Sterling, Aaron Strockis, Joyce Tsai, Lucy Visser, Mourad Wahba, Samuel Williams, Allan H Young, Paula Ywema, Sidney Zisook, Ekaterina Malievskaia
The New England journal of medicine November 3, 2022 DOI: 10.1056/nejmoa2206443 via PubMed
Summary
AI-generated from the abstractA single 25 mg dose of psilocybin, but not 10 mg, reduced depression scores more than a 1 mg control dose over three weeks in adults with treatment-resistant depression. In this phase 2 trial, 233 participants were randomly assigned to 25 mg, 10 mg, or 1 mg of synthetic psilocybin with psychological support. The 25 mg group showed an average 12-point drop on the MADRS depression scale versus a 5.4-point drop in the 1 mg group, a significant difference. The 10 mg group did not differ significantly from control. Response and remission rates at three weeks supported the primary result, but sustained response at 12 weeks was not significantly different.
Study at a glance
| Characteristics | Phase 2 double-blind randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 233 |
| Population | Adults with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg, 10 mg, or 1 mg |
| Duration | Single dose, 3-week primary endpoint, 12-week follow-up for sustained response |
| Topics | Depression |
| Keywords | Psilocybin therapy Psychedelic medicine Mental health research Clinical trials |
| Citations | 1,095 |
| Registration | NCT03775200 |
| Key finding | A single 25 mg dose of psilocybin, but not 10 mg, significantly reduced depression scores at three weeks compared to a 1 mg control dose in treatment-resistant depression. |
Abstract
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression). Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits). A total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group. The mean MADRS total score at baseline was 32 or 33 in each group. Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18). In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results. Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness. Suicidal ideation or behavior or self-injury occurred in all dose groups. In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder. (Funded by COMPASS Pathfinder; EudraCT number, 2017-003288-36; ClinicalTrials.gov number, NCT03775200.).